Perioperative immunotherapy for hepatocellular carcinoma

Bin XU; Meiling LI; Huichuan SUN

doi:10.3969/j.issn.1001-5256.2022.05.002

Volume 38 Issue 5

May 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(5): 980-984

PDF( 1893 KB)

Perioperative immunotherapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.05.002

Department of Liver Tumor Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Research funding:

National Key Basic Research Program (973 Program) (2015CB554005);

National Natural Science Foundation of China (81372655);

National Natural Science Foundation of China (81472224);

National Natural Science Foundation of China (81672326);

Leading Investigator Program of Shanghai Municipal Government (17XD1401100)

More Information

Corresponding author: SUN Huichuan, sun.huichuan@zs-hospital.sh.cn(ORCID: 0000-0003-3761-7058)
Received Date: 2022-01-14
Accepted Date: 2022-02-15
Published Date: 2022-05-20

Abstract

Abstract

Hepatocellular carcinoma (HCC) greatly threatens the life and health of Chinese people. Most patients with HCC are already in the advanced stage when attending the hospital and are not eligible for radical treatment, and patients in the early stage of HCC who are eligible for radical treatment still face a high risk of recurrence after surgery. In recent years, immunotherapy based on immune checkpoint inhibitors (ICIs) has made great progress in the treatment of advanced HCC, and perioperative immunotherapy for HCC is attracting more and more attention. Immunotherapy in the perioperative period of HCC can improve the feasibility of hepatectomy, reduce the recurrence rate after hepatectomy, and prolong the survival of patients. This article discusses the application of ICIs-based immunotherapy in the perioperative period of HCC and the issues that need to be considered, so as to provide new ideas for perioperative immunotherapy for HCC.
- Carcinoma, hepatocellular,
- Immunotherapy,
- Neoadjuvant therapy,
- Conversion therapy,
- Adjuvant therapy

FullText(HTML)

References(32)

References

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[3]	ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
[4]	LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
[5]	CHEN L, FLIES DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013, 13(4): 227-242. DOI: 10.1038/nri3405.
[6]	HE X, XU C. Immune checkpoint signaling and cancer immunotherapy[J]. Cell Res, 2020, 30(8): 660-669. DOI: 10.1038/s41422-020-0343-4.
[7]	YAU T, PARK J W, FINN R S, et al. CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) [J]. Ann Oncol, 2019, 30: v874-v875. DOI: 10.1093/annonc/mdz394.029
[8]	FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.
[9]	ZHU XD, LI KS, SUN HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects[J]. Genes Dis, 2020, 7(3): 359-369. DOI: 10.1016/j.gendis.2020.02.002.
[10]	SUN HC. Conversion surgery for unresectable or advanced hepatocellular carcinoma[J]. J Abdominal Surg, 2021, 34(2): 85-87. DOI: 10.3969/j.issn.1003-5591.2021.02.001. 孙惠川. 不可切除和中晚期肝癌的转化切除[J]. 腹部外科, 2021, 34(2): 85-87. DOI: 10.3969/j.issn.1003-5591.2021.02.001.
[11]	PINATO DJ, FESSAS P, SAPISOCHIN G, et al. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma[J]. Hepatology, 2021, 74(1): 483-490. DOI: 10.1002/hep.31697.
[12]	MILLER BC, SEN DR, AL ABOSY R, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade[J]. Nat Immunol, 2019, 20(3): 326-336. DOI: 10.1038/s41590-019-0312-6.
[13]	LIU J, O'DONNELL JS, YAN J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome[J]. Oncoimmunology, 2019, 8(5): e1581530. DOI: 10.1080/2162402X.2019.1581530.
[14]	YARCHOAN M, ZHU Q, DURHAM J N, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC) [J]. J Clin Oncol, 2021, 39(3_suppl): 335. DOI: 10.1200/JCO.2021.39.3_suppl.335
[15]	XIA Y, WANG P, PU L, et al. Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase Ⅱ study [J]. J Clin Oncol, 2021, 39(15_suppl): 4082. DOI: 10.1200/JCO.2021.39.15_suppl.4082
[16]	KASEB AO, HASANOV E, CAO H, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218. DOI: 10.1016/S2468-1253(21)00427-1.
[17]	YU YQ, TANG ZY, ZHOU XD, et al. Staged treatment of large hepatocellular carcinoma [J]. Chin J Surg, 1983, 21(2): 92-93. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906049.htm 余业勤, 汤钊猷, 周信达, 等. 大肝癌的分阶段治疗[J]. 中华外科杂志, 1983, 21(2): 92-93. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906049.htm
[18]	ZHU XD, HUANG C, SHEN YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4): 320-329. DOI: 10.1159/000514313.
[19]	ZHANG W, HU B, HAN J, et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: A pilot study of ten patients[J]. Front Oncol, 2021, 11: 747950. DOI: 10.3389/fonc.2021.747950.
[20]	YANG X, XU H, ZUO B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy[J]. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442. DOI: 10.21037/hbsn-21-188.
[21]	ZHANG J, ZHANG X, MU H, et al. Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: A retrospective study[J]. Front Oncol, 2021, 11: 729764. DOI: 10.3389/fonc.2021.729764.
[22]	KRALL JA, REINHARDT F, MERCURY OA, et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy[J]. Sci Transl Med, 2018, 10(436): eaan3464. DOI: 10.1126/scitranslmed.aan3464.
[23]	ISHIKAWA M, NISHIOKA M, HANAKI N, et al. Perioperative immune responses in cancer patients undergoing digestive surgeries[J]. World J Surg Oncol, 2009, 7: 7. DOI: 10.1186/1477-7819-7-7.
[24]	DBROWSKA AM, SŁOTWIŃSKI R. The immune response to surgery and infection[J]. Cent Eur J Immunol, 2014, 39(4): 532-537. DOI: 10.5114/ceji.2014.47741.
[25]	KUDO M. Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis, ASCO Annual Meeting, F, 2021[C]. American Society of Clinical Oncology.
[26]	YANG X, SUN H, HU B, et al. 944P Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC Ⅱ and Ⅲ stage: A single-center prospective phase Ⅱ trial [J]. Annals Oncol, 2021, 32: S824.
[27]	DUAN J, CUI L, ZHAO X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: A systematic review and meta-analysis[J]. JAMA Oncol, 2020, 6(3): 375-384. DOI: 10.1001/jamaoncol.2019.5367.
[28]	BERTRAND A, KOSTINE M, BARNETCHE T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis[J]. BMC Med, 2015, 13: 211. DOI: 10.1186/s12916-015-0455-8.
[29]	ZHU A X, FINN R S, IKEDA M, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2020, 38(15_suppl): 4519. DOI: 10.1200/JCO.2020.38.15_suppl.4519
[30]	XU B, SUN HC. Camrelizumab: An investigational agent for hepatocellular carcinoma[J]. Expert Opin Investig Drugs, 2021: 1-10. DOI: 10.1080/13543784.2022.2022121.
[31]	SANGRO B, CHAN SL, MEYER T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 320-341. DOI: 10.1016/j.jhep.2019.10.021.
[32]	SHI GM, HUANG XY, REN ZG, et al. Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors (2021 edition)[J]. Chin J Dig Surg, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594. 施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (777) PDF downloads(175)

Perioperative immunotherapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.05.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Perioperative immunotherapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.05.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content